Baricitinib Shows Promise in Polymyalgia Rheumatica
Baricitinib can effectively treat polymyalgia rheumatica (PMR) without the use of oral glucocorticoids, according to results from a small, randomized, double-blind, placebo-controlled study. Among the 18 patients randomly assigned to the oral Janus kinase (JAK) inhibitor baricitinib, 14 achieved a C-reactive protein PMR activity score (CRP PMR-AS) of 10 or less after 12 weeks of … Read more